JP2024161509A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024161509A5 JP2024161509A5 JP2024136804A JP2024136804A JP2024161509A5 JP 2024161509 A5 JP2024161509 A5 JP 2024161509A5 JP 2024136804 A JP2024136804 A JP 2024136804A JP 2024136804 A JP2024136804 A JP 2024136804A JP 2024161509 A5 JP2024161509 A5 JP 2024161509A5
- Authority
- JP
- Japan
- Prior art keywords
- multivalent antibody
- linker comprises
- hinge sequence
- antibody according
- multivalent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650467P | 2018-03-30 | 2018-03-30 | |
| US62/650,467 | 2018-03-30 | ||
| PCT/NL2019/050199 WO2019190327A2 (en) | 2018-03-30 | 2019-03-29 | Multivalent antibody |
| JP2021502692A JP7603578B2 (ja) | 2018-03-30 | 2019-03-29 | 多価抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502692A Division JP7603578B2 (ja) | 2018-03-30 | 2019-03-29 | 多価抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024161509A JP2024161509A (ja) | 2024-11-19 |
| JP2024161509A5 true JP2024161509A5 (https=) | 2025-04-02 |
Family
ID=66349617
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502692A Active JP7603578B2 (ja) | 2018-03-30 | 2019-03-29 | 多価抗体 |
| JP2024136804A Pending JP2024161509A (ja) | 2018-03-30 | 2024-08-16 | 多価抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502692A Active JP7603578B2 (ja) | 2018-03-30 | 2019-03-29 | 多価抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11952424B2 (https=) |
| EP (1) | EP3774885A2 (https=) |
| JP (2) | JP7603578B2 (https=) |
| KR (1) | KR20200139189A (https=) |
| CN (1) | CN111936514A (https=) |
| AR (1) | AR115320A1 (https=) |
| AU (2) | AU2019243665B2 (https=) |
| BR (1) | BR112020019795A2 (https=) |
| CA (1) | CA3094318A1 (https=) |
| EA (1) | EA202091871A1 (https=) |
| IL (1) | IL277672A (https=) |
| MA (1) | MA52212A (https=) |
| MX (2) | MX2020010267A (https=) |
| NZ (1) | NZ767923A (https=) |
| PH (1) | PH12020551504A1 (https=) |
| SG (1) | SG11202009036YA (https=) |
| TW (1) | TW202003569A (https=) |
| WO (1) | WO2019190327A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA52212A (fr) | 2018-03-30 | 2021-02-17 | Merus Nv | Anticorps multivalent |
| CA3124688A1 (en) * | 2018-12-31 | 2020-07-09 | Merus N.V. | Truncated multivalent multimers |
| JP7443376B2 (ja) | 2018-12-31 | 2024-03-05 | メルス ナムローゼ フェンノートシャップ | 混合結合ドメイン |
| CN114605546A (zh) * | 2019-03-29 | 2022-06-10 | 美勒斯公司 | Cd3结合分子 |
| TW202546002A (zh) | 2019-03-29 | 2025-12-01 | 荷蘭商美勒斯公司 | Cd3結合分子 |
| AU2020268684C1 (en) | 2019-05-09 | 2026-04-02 | Merus B.V. | Variant domains for multimerizing proteins and separation thereof |
| CN116199780A (zh) | 2019-12-24 | 2023-06-02 | 美勒斯公司 | TGF-β-RII结合蛋白质 |
| IL294368A (en) | 2020-01-29 | 2022-08-01 | Merus Nv | Means and method for modulating mixed effects in immune cells |
| WO2021200673A1 (ja) * | 2020-03-31 | 2021-10-07 | 公立大学法人大阪 | 多重特異性抗体及びその製造方法 |
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| EP4149627A4 (en) * | 2020-05-14 | 2024-05-29 | The General Hospital Corporation | POLYPEPTIDE AGONISTS OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY |
| WO2021226984A1 (zh) | 2020-05-15 | 2021-11-18 | 三生国健药业（上海）股份有限公司 | 一种抗pd-1和pd-l1的四价双特异性抗体 |
| BR112022023697A2 (pt) | 2020-05-21 | 2022-12-20 | Merus Nv | Métodos e meios para a produção de moléculas semelhantes a ig |
| AU2021378290B2 (en) * | 2020-11-11 | 2025-10-30 | Nautilus Subsidiary, Inc. | Affinity reagents having enhanced binding and detection characteristics |
| CN115536749A (zh) * | 2021-06-29 | 2022-12-30 | 三生国健药业（上海）股份有限公司 | 三特异性抗体、其制备方法和用途 |
| US12365743B2 (en) | 2022-02-23 | 2025-07-22 | Xencor, Inc. | Anti-CD28 x anti-PSMA antibodies |
| US20240117030A1 (en) * | 2022-03-03 | 2024-04-11 | Pfizer Inc. | Multispecific antibodies and uses thereof |
| CN119365490A (zh) * | 2022-04-13 | 2025-01-24 | Xencor股份有限公司 | 结合pd-l1、pd-l2和/或cd28的抗体 |
| KR20250129720A (ko) | 2022-12-27 | 2025-08-29 | 메뤼스 엔.페. | 이중특이적 단백질을 생성하는 방법 |
| WO2024144400A1 (en) * | 2022-12-30 | 2024-07-04 | Merus N.V. | Promiscuous cd3 binding molecules |
| CN117946246B (zh) * | 2023-02-23 | 2024-08-06 | 暨南大学 | 一种识别mage-a3抗原短肽的t细胞受体及其应用 |
| WO2024206568A2 (en) * | 2023-03-31 | 2024-10-03 | Ibio, Inc. | Anti-cd3 antibodies |
| WO2025221674A1 (en) * | 2024-04-15 | 2025-10-23 | Eli Lilly And Company | Baffr x cd3 bispecific antibodies and methods of use |
| WO2025230409A1 (en) | 2024-04-30 | 2025-11-06 | Merus N.V. | Multispecific antibody-drug conjugates |
| WO2025230410A1 (en) | 2024-04-30 | 2025-11-06 | Merus N.V. | Multispecific antibody-drug conjugates |
| WO2026013015A1 (en) * | 2024-07-09 | 2026-01-15 | Merus N.V. | Multispecific binding moieties comprising calr and cd3 binding domains |
| WO2026018064A1 (en) | 2024-07-16 | 2026-01-22 | Merus N.V. | Multispecific multi-drug antibody-drug conjugates |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4118120A1 (de) * | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
| CA2410551A1 (en) * | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
| WO2002008293A2 (en) * | 2000-07-25 | 2002-01-31 | Immunomedics Inc. | Multivalent target binding protein |
| DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2147594B1 (en) | 2008-06-27 | 2013-11-13 | Merus B.V. | Antibody producing non-human mammals |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| CN102459591B (zh) | 2009-05-20 | 2015-05-13 | 诺维莫尼公司 | 合成性的多肽文库以及用于建立具有天然多样性的多肽变体的方法 |
| PE20120540A1 (es) * | 2009-05-27 | 2012-05-09 | Hoffmann La Roche | Anticuerpos triespecificos o tetraespecificos |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| WO2011084255A2 (en) | 2009-12-17 | 2011-07-14 | Novimmune S.A. | Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| UY33826A (es) | 2010-12-22 | 2012-07-31 | Abbott Lab | Proteínas de unión con dominios trivariables y sus usos |
| CA2843158A1 (en) * | 2011-08-26 | 2013-03-07 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| US20150203591A1 (en) * | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| HUE042040T2 (hu) | 2012-09-27 | 2019-06-28 | Merus Nv | Bispecifikus IGG antitestek mint T-sejt kapcsolók |
| WO2014122143A1 (en) | 2013-02-05 | 2014-08-14 | Engmab Ag | Method for the selection of antibodies against bcma |
| EP2961770A1 (en) | 2013-02-26 | 2016-01-06 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| US10519251B2 (en) * | 2013-12-30 | 2019-12-31 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| JP6771385B2 (ja) | 2014-02-28 | 2020-10-21 | メルス ナムローゼ フェンノートシャップ | 二重特異性抗体および医薬組成物 |
| WO2015130173A1 (en) | 2014-02-28 | 2015-09-03 | Merus B.V. | Antibody that binds erbb-2 and erbb-3 |
| EA035419B9 (ru) | 2014-05-29 | 2020-08-07 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы и способы их применения |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| CA2963696A1 (en) | 2014-10-09 | 2016-04-14 | Engmab Ag | Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer |
| EP3204415B1 (en) | 2014-10-09 | 2020-06-17 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and ror1 |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| WO2016105450A2 (en) * | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| US9914777B2 (en) * | 2015-07-10 | 2018-03-13 | Merus N.V. | Human CD3 binding antibody |
| SI3331910T1 (sl) | 2015-08-03 | 2020-07-31 | Engmab Sarl | Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA) |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| SMT202100230T1 (it) * | 2015-10-23 | 2021-07-12 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Molecole di legame che inibiscono la crescita tumorale |
| PT3433273T (pt) | 2016-03-25 | 2022-02-21 | Biomunex Pharmaceuticals | Moléculas de ligação a cd38 e pd-l1 |
| MX2018013038A (es) * | 2016-04-27 | 2019-03-28 | Pfizer | Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos. |
| SG11201809316XA (en) | 2016-04-28 | 2018-11-29 | Biomunex Pharmaceuticals | Bispecific antibodies targeting egfr and her2 |
| WO2018014260A1 (en) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| ES2981272T3 (es) * | 2016-09-23 | 2024-10-08 | Merus Nv | Moléculas de unión que modulan una actividad biológica expresada por una célula |
| CN110177805B (zh) | 2016-10-19 | 2024-04-02 | 英温拉公司 | 抗体构建体 |
| JP7267914B2 (ja) | 2016-11-02 | 2023-05-02 | エンクマフ エスアーエールエル | Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬 |
| US20200291130A1 (en) * | 2017-03-31 | 2020-09-17 | Merus N.V. | Antibodies for the treatment of erbb-2/erbb-3 positive tumors |
| IL269656B2 (en) * | 2017-03-31 | 2024-06-01 | Merus Nv | Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene |
| CN118027197A (zh) * | 2017-07-06 | 2024-05-14 | 美勒斯公司 | 调节由细胞表达的生物活性的抗体 |
| AU2018296067B2 (en) * | 2017-07-06 | 2021-06-10 | Merus B.V. | Binding molecules that modulate a biological activity expressed by a cell |
| MX2020000055A (es) * | 2017-07-06 | 2020-08-06 | Merus Nv | Anticuerpos biespecificos antiproteina 1 de muerte celular programada (pd-1) -anti inmunoglobulina de celulas t y dominio de mucina que contiene -3 (tim-3). |
| SG11202001050PA (en) * | 2017-08-09 | 2020-03-30 | Merus Nv | Antibodies that bind egfr and cmet |
| WO2019108065A1 (en) * | 2017-12-01 | 2019-06-06 | Merus N.V. | Use of bispecific antibody and il-15 for combination therapy |
| MA52212A (fr) | 2018-03-30 | 2021-02-17 | Merus Nv | Anticorps multivalent |
| JP7443376B2 (ja) * | 2018-12-31 | 2024-03-05 | メルス ナムローゼ フェンノートシャップ | 混合結合ドメイン |
| AU2020268684C1 (en) * | 2019-05-09 | 2026-04-02 | Merus B.V. | Variant domains for multimerizing proteins and separation thereof |
| IL293215A (en) * | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors that bind bcma and cd19 and their uses |
| IL294368A (en) * | 2020-01-29 | 2022-08-01 | Merus Nv | Means and method for modulating mixed effects in immune cells |
-
2019
- 2019-03-29 MA MA052212A patent/MA52212A/fr unknown
- 2019-03-29 SG SG11202009036YA patent/SG11202009036YA/en unknown
- 2019-03-29 NZ NZ767923A patent/NZ767923A/en unknown
- 2019-03-29 EA EA202091871A patent/EA202091871A1/ru unknown
- 2019-03-29 WO PCT/NL2019/050199 patent/WO2019190327A2/en not_active Ceased
- 2019-03-29 KR KR1020207030642A patent/KR20200139189A/ko not_active Ceased
- 2019-03-29 MX MX2020010267A patent/MX2020010267A/es unknown
- 2019-03-29 AR ARP190100836A patent/AR115320A1/es unknown
- 2019-03-29 AU AU2019243665A patent/AU2019243665B2/en active Active
- 2019-03-29 CN CN201980023259.9A patent/CN111936514A/zh active Pending
- 2019-03-29 EP EP19721163.4A patent/EP3774885A2/en active Pending
- 2019-03-29 BR BR112020019795-5A patent/BR112020019795A2/pt unknown
- 2019-03-29 JP JP2021502692A patent/JP7603578B2/ja active Active
- 2019-03-29 US US16/370,346 patent/US11952424B2/en active Active
- 2019-03-29 TW TW108111354A patent/TW202003569A/zh unknown
- 2019-03-29 CA CA3094318A patent/CA3094318A1/en active Pending
-
2020
- 2020-09-16 PH PH12020551504A patent/PH12020551504A1/en unknown
- 2020-09-29 IL IL277672A patent/IL277672A/en unknown
- 2020-09-29 MX MX2026002407A patent/MX2026002407A/es unknown
-
2023
- 2023-09-01 AU AU2023222983A patent/AU2023222983A1/en active Pending
-
2024
- 2024-02-13 US US18/440,582 patent/US20240360217A1/en active Pending
- 2024-02-13 US US18/440,607 patent/US20240352127A1/en active Pending
- 2024-08-16 JP JP2024136804A patent/JP2024161509A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024161509A5 (https=) | ||
| JP6753945B2 (ja) | 抗人ｐｄ−ｌ１人源化単クローン抗体及び応用 | |
| Wu et al. | Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules | |
| Schuster | Bispecific antibodies for the treatment of lymphomas: Promises and challenges | |
| TWI676681B (zh) | 具抗原專一性的t細胞及其用途 | |
| CN113677359A (zh) | Cd25抗体 | |
| CN109219619A (zh) | 抗lag-3抗体 | |
| AU680685B2 (en) | Retargeting antibodies | |
| JPH03500005A (ja) | 組換えｄｎａタンパクの製造方法 | |
| JP2006515503A5 (https=) | ||
| KR960704575A (ko) | 항원-특이적 t 세포의 내성을 유도하는 방법(methods for inducing antigen-specific tcell tolerance) | |
| JP2020007318A5 (https=) | ||
| AU2022273136A1 (en) | Binding molecule against dll3 and use thereof | |
| JP2024514109A (ja) | 抗ｃｎｔｎ４抗体及びその使用 | |
| JP7418326B2 (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| JPH01501201A (ja) | 抗体 | |
| Sandeep et al. | Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics | |
| TW201904999A (zh) | 抗gitr抗體、其抗原結合片段及其醫藥用途 | |
| Silverstein | Labeled antigens and antibodies: the evolution of magic markers and magic bullets | |
| Shinde et al. | Polyvalency: an emerging trend in the development of clinical antibodies | |
| CN118702814A (zh) | 一种抗ngf单克隆抗体及其应用 | |
| Winter | Antibody engineering | |
| JP2010529950A5 (https=) | ||
| CN110577598A (zh) | 抗sFcεRIα单克隆抗体及其应用 | |
| CN113549152B (zh) | 一种抗basigin人源化抗体及其应用 |